Clinuvel Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 11, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Market Capitalization	346	341	514	588	506	1,137
Market Cap Growth	-	-33.59%	-12.65%	16.31%	-55.55%	29.97%
Enterprise Value	182	212	398	495	438	1,084
Last Close Price	6.74	6.78	9.73	11.86	10.16	22.59
PE Ratio	15.94	14.38	21.60	28.87	35.14	61.34
PS Ratio	5.39	5.48	8.73	11.28	11.16	31.39
PB Ratio	2.08	2.16	3.79	5.37	5.84	15.36
P/TBV Ratio	2.08	2.16	3.80	5.37	5.85	15.39
P/FCF Ratio	12.22	12.75	24.46	24.62	18.61	82.41
P/OCF Ratio	12.10	12.66	20.77	23.93	18.40	78.75
EV/Sales Ratio	2.83	3.40	6.76	9.50	9.68	29.91
EV/EBITDA Ratio	6.23	6.94	12.09	16.71	17.68	49.73
EV/EBIT Ratio	6.33	7.05	12.28	16.86	17.89	50.60
EV/FCF Ratio	6.41	7.91	18.95	20.73	16.13	78.52
Debt / Equity Ratio	0.00	0.00	0.00	0.01	0.01	0.01
Debt / EBITDA Ratio	0.01	0.01	0.02	0.02	0.03	0.04
Debt / FCF Ratio	0.01	0.01	0.03	0.03	0.03	0.07
Net Debt / Equity Ratio	-0.93	-0.93	-0.90	-0.95	-0.96	-0.82
Net Debt / EBITDA Ratio	-5.33	-4.80	-3.71	-3.50	-3.34	-2.80
Net Debt / FCF Ratio	-5.81	-5.48	-5.81	-4.34	-3.05	-4.42
Asset Turnover	0.38	0.38	0.42	0.46	0.52	0.51
Inventory Turnover	1.12	0.87	0.77	1.33	3.69	1.87
Quick Ratio	13.98	9.24	8.33	7.02	10.03	11.35
Current Ratio	14.64	9.66	8.81	7.44	10.24	11.81
Return on Equity (ROE)	13.96%	16.30%	19.39%	21.09%	18.62%	28.95%
Return on Assets (ROA)	10.62%	11.37%	14.29%	16.34%	17.60%	18.78%
Return on Invested Capital (ROIC)	193.72%	172.36%	236.84%	419.57%	190.89%	229.04%
Return on Capital Employed (ROCE)	17.10%	18.70%	23.60%	26.20%	27.30%	28.60%
Earnings Yield	6.27%	6.95%	4.63%	3.46%	2.84%	1.63%
FCF Yield	8.18%	7.84%	4.09%	4.06%	5.38%	1.21%
Dividend Yield	0.39%	0.48%	0.34%	0.28%	0.27%	0.08%
Payout Ratio	6.14%	6.92%	6.93%	6.46%	5.92%	5.00%
Buyback Yield / Dilution	-0.37%	1.27%	1.52%	-0.08%	-1.26%	-1.33%
Total Shareholder Return	0.02%	1.75%	1.87%	0.21%	-0.99%	-1.25%

SEC Filings: 10-K · 10-Q